USC-Exos

USC-Exos, or exosomes derived from urine-derived stem cells, have shown promise in several therapeutic areas by leveraging their cellular communication capabilities and deliver specific bioactive molecules.

A significant mechanism of action involves the delivery of microRNAs (miRNAs), specifically miR-26a-5p and miR-122-5p, which have been identified as pivotal in targeting processes like renal fibrosis and inflammation. For instance, miR-26a-5p works by targeting NRAS, a gene involved in cell signaling pathways, to mitigate kidney fibrosis (PMID: 41874363). Additionally, miR-122-5p inhibits fibrosis and inflammation in kidney injury by modulating the SOX2 pathway (PMID: 38617751).

USC-Exos also play a role in bone regeneration. They regulate energy metabolism to promote alveolar bone regeneration when used with biomimetic 3D-printed scaffolds (PMID: 41608575). Exosomes also facilitate rotator cuff healing by mediating the action of bone marrow mesenchymal stem cells (PMID: 36879794) and accelerate bone regeneration when delivered via injectable hydrogels (PMID: 36846309).

Furthermore, in ischemia-reperfusion acute kidney injury, USC-Exos may inhibit cell death processes like pyroptosis through the action of specific circular RNAs and their downstream effects (PMID: 38412628).

While the evidence shows encouraging results across various applications and conditions, further research and clinical trials are essential to fully understand and validate these mechanisms.

Disclaimer: This content is for informational purposes only and is not a substitute for professional medical advice. Always consult a healthcare provider for medical advice and treatment.